SFX by Ex Libris Inc.

Title:	In pursuit of α4β2 nicotinic receptor partial agonists for smoking cessation: Carbon analogs of (−)-cytisine
Source:	Bioorganic & Medicinal Chemistry Letters [0960-894X] Coe, Jotham yr:2005

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Mihalak, Karla B B. "Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors." Molecular pharmacology 70.3 (2006): 801-5.
description	2.	Niaura, R. Nature reviews. Drug discovery 5.7 (2006): 537-8.
description	3.	Hwu, Jih h. "New Nordihydroguaiaretic Acid Derivatives as Anti-HIV Agents." Bioorganic & medicinal chemistry letters 18.6 (2008): 1884-1888.
description	4.	Mansbach, R. "Effects of the competitive nicotinic antagonist erysodine on behavior occasioned or maintained by nicotine: comparison with mecamylamine." Psychopharmacology 148.3 (2000): 234-242.
description	5.	Pasikanti, S. "An efficient synthesis of varenicline." Tetrahedron letters 51.1 (2010): 151-152.
description	6.	Kuehn, Bridget M. "New reports examine psychiatric risks of varenicline for smoking cessation.(Report)." JAMA (Chicago, Ill.) 307.2 (2012): 129-.
description	7.	Rollema, H. "Pharmacological profile of the alpha(4)beta(2) nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid." Neuropharmacology 52.3 (2007): 985-994.
description	8.	Punzi, A. "Synthesis of Symmetrical Ketones from Grignard Reagents and 1,1 '-Carbonyldiimidazole." Synthesis 2009.14 (2009): 2316-2318.
description	9.	Laviolette, Steven R R. "The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour." Nature reviews. Neuroscience 5.1 (2003): 55-65.
description	10.	Lam, S. "Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation." Cardiology in review 15.3 (2007): 154-61.
description	11.	Foulds, J. "The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline." International journal of clinical practice 60.5 (2006): 571-6.
description	12.	Potts, Lisa A. "Varenicline: the newest agent for smoking cessation." American journal of health-system pharmacy 64.13 (2007): 1381-4.
description	13.	Meyers, Ross O. "Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid." Bioorganic & medicinal chemistry letters 19.16 (2009): 4752-5.
description	14.	Hu, B. "Convenient synthesis of acetonide-protected 3,4-dihydroxyphenylalanine (DOPA) for Fmoc solid-phase peptide synthesis." Tetrahedron letters 49.38 (2008): 5519-5521.
description	15.	Sharma, R. "1,1 '-carbonyldiimidazole (CDI)." Synlett 2007.19 (2007): 3073-3074.
description	16.	Evers, A. "Virtual Screening of Biogenic Amine-Binding G-Protein Coupled Receptors: Comparative Evaluation of Protein- and Ligand-Based Virtual Screening Protocols." Journal of medicinal chemistry 48.17 (2005): 5448-5465.
description	17.	ARNERIC, Stephen P. "Neuronal nicotinic receptors: A perspective on two decades of drug discovery research." Biochemical Pharmacology 74.8 (2007): 1092-101.
description	18.	Arias, Hugo R. "Molecular mechanisms and binding site locations for noncompetitive antagonists of nicotinic acetylcholine receptors." The international journal of biochemistry & cell biology 38.8 (2006): 1254-1276.
description	19.	Loughead, J. "Effects of the α4β2 partial agonist varenicline on brain activity and working memory in abstinent smokers." Biological psychiatry 67.8 (2010): 715-721.
description	20.	Mansbach, Eric P S. "Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation." Journal of medicinal chemistry 48.10 (2005): 3474-7.